Navigation Links
Encouraging Clinical Data From Multicenter Phase 1/2 Trial On Actinium's Actimab-A Presented At American Society Of Hematology Annual Meeting
Date:12/9/2013

NEW YORK, Dec. 9, 2013 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (OTCQB: ATNM.OB) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, were presented in a poster session on Saturday, December 7, 2013 at the American Society of Hematology's (ASH) 55th Annual Meeting and Exposition in New Orleans.  Data demonstrated antileukemic effect in 67% of evaluable patients and 47% of patients treated across all dose levels.  Participants in the trial were newly diagnosed acute myeloid leukemia (AML) patients with poor prognostic factors unable or unwilling to receive standard chemotherapy.

Abstract presented at this year's ASH meeting reported the initial data from this study demonstrating that administration of Actimab-A (monoclonal antibody HuM195 labeled with actinium 225) in fractionated doses is feasible, safe and has antileukemic activity.

Abstract Information

The Actimab-A abstract information is as follows:

Session: 615. Acute Myeloid Leukemia: Therapy, excluding Transplantation: Poster I

Abstract #1460:  "Phase I Trial Of The Targeted Alpha-Particle Nano-Generator Actinium-225 (225Ac)-Lintuzumab (Anti-CD33) In Combination With Low-Dose Cytarabine (LDAC) For Older Patients With Untreated Acute Myeloid Leukemia (AML)"

An abstract summarizing the data is published on the ASH website at (https://ash.confex.com/ash/2013/webprogram/Paper63558.html)

About Actimab-A™

Actimab-A is a drug candidate construct made using Actinium Pharmaceuticals' proprietary patented technology for arming monoclonal antibodies with alpha emitters actinium 225 and bismuth 213.  Antibodies are used as high precision delivery systems that bring powerful alpha emitters into or immediately next to targeted cancer cells.  Actimab-A consists of the Lintuzumab monoclonal antibody and actinium 225.

Actinium-225 decays by giving off high-energy alpha particles, which kill cancer cells. When actinium decays, it produces a series of daughter atoms, each of which gives off its own alpha particle, increasing the chances that the cancer cell will be destroyed.  The technology was first developed by Dr. David Scheinberg at Memorial Sloan Kettering Cancer Center. 

Lintuzumab is a monoclonal antibody that targets CD33, found on myeloid leukemia cells. It is the humanized version of M195, the antibody initially developed by Dr. David Scheinberg of Memorial Sloan Kettering Cancer Center.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc. (OTCQB: ATNM.OB), is a New York based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers.  Actinium's targeted radiotherapy is based on its proprietary delivery platform for the therapeutic utilization of alpha emitting actinium-225 and bismuth-213 radiopharmaceuticals in conjunction with monoclonal antibodies.  The Company also develops other radiopharmaceuticals for select applications.

For more information:

Visit our web site www.actiniumpharmaceuticals.com

Contact:

Media
Dennis S. Dobson Jr.
Tel: (203) 258-0159
Email: dennisdobsonjr@dobsonmediagroup.com

Media and Investors:
Actinium Pharmaceuticals, Inc.
Corey Sohmer,
Phone: (646) 459-4201
E-mail: csohmer@actiniumpharmaceuticals.com

Forward-Looking Statement for Actinium Pharmaceuticals, Inc.

This news release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.


'/>"/>
SOURCE Actinium Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Maroon 5 Lead Singer Adam Levine and Shire Announce "The Own It Project," Encouraging Adults with Attention-Deficit/Hyperactivity Disorder to Tell Their Stories Through a National Contest
2. ProNAi Expands Management Team and Presents Encouraging Phase I Study Results for Lead Cancer Drug at Cancer Meeting
3. Omeros Announces Encouraging Data from Phase 1 Clinical Trial for PDE10 Program
4. Rx-to-OTC Switching Strategies - New Switching Opportunities in Weight Management and Smoking Cessation, but Encouraging the Uptake of Self-Medication Remains a Challenge
5. DelMar Pharma Presents Encouraging Data From Ongoing Phase I/II GBM Clinical Trial With VAL-083
6. Isis Pharmaceuticals Reports Encouraging Data on ISIS-STAT3rx in Patients With Cancer
7. Epizymes EPZ-5676 DOT1L Inhibitor Demonstrates Encouraging Initial Findings in an Ongoing Phase 1 Dose Escalation Study
8. Clinical Trial at Evergreen Healthcare Shows Intestinal Gel Reduces Symptoms of Advanced Parkinsons Disease
9. Asubio Initiates Landmark Clinical Study in Spinal Cord Injury
10. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
11. AtheroNova Signs Agreement for Development of Clinical Trial Supplies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... 30, 2017 Revenue Prospects by Product Type ... COPD) and Geography Respiratory Inhalers - our new study ... Respiratory Inhalers market heading? If you are involved in this sector ... shows you the potential revenues streams to 2027, assessing data, trends, ... ...
(Date:3/29/2017)... , March 29, 2017 Wound care devices ... healing of the wound. The industry mainly consists of ... for the treatment of wounds caused by mechanical, chemical, ... to diseases such as diabetes, skin related diseases, immunological ... Europe was the largest region in the ...
(Date:3/29/2017)... , March 29, 2017  BioSpecifics Technologies Corp. ... continues to develop collagenase based-therapies with a first ... marketed as XIAFLEX ®  in the U.S. and ... present a corporate overview at the upcoming 16 ... April 5, 2017 at 8:00 a.m. ET in ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... 2017 , ... ARI Network Services, Inc. (NASDAQ: ARIS) announced today that Rhino ... its network of more than 650 U.S.-based dealers. Rhino, a member of the Alamo ... flail mowers and cutters, rear blades, post hole diggers, pasture renovators, tillers, disc mowers ...
(Date:3/29/2017)... ... ... pollen is the main cause of hay fever in the United States, with an estimated ... from May to July each year; with the worst time for sufferers being June and ... ( http://www.haymax.us ) provide an effective defense against grass pollen; they are proven in independent ...
(Date:3/29/2017)... ... March 30, 2017 , ... Sports Brand EXOUS Bodygear announced ... retails normally at $29.97; for the remaining days of March, the price will be ... to a special price of just $10 (regular retail price $19.97). , The special ...
(Date:3/29/2017)... ... 2017 , ... Based on research from Guardian’s Fourth Annual ... trying to balance both short-term and long-term benefits demands. Are employers struggling ... complexity, companies are finding that the short-term strategies used to control costs, improve ...
(Date:3/29/2017)... ... March 29, 2017 , ... How big ... outpatient facilities, and who are the most active developers? , In the ... Healthcare Real Estate Insights (HREI) found that outpatient medical real estate development projects ...
Breaking Medicine News(10 mins):